BrainChild
BrainChild is a biotech company developing locoregional CAR T therapies for pediatric brain tumors, founded in 2023 and headquartered in...
Facts
- HQ
- Seattle
- Sectors
- Biotech, Healthcare, Cell therapy, Immunotherapy
- Founded
- 2023
BrainChild Bio Raises $116M Series A on Sept. 8 to Fund Phase 2 B7-H3 CAR T Trial for DIPG
BrainChild Bio raised $116 million in a Series A on Sept. 8 to fund a registrational Phase 2 trial of BCB-276, a B7-H3 CAR T therapy delivered directly into cerebrospinal fluid for DIPG, and to advance a triple-antigen glioblastoma program. The Seattle Children’s spinout aims to bypass the blood-brain barrier with intrathecal delivery after promising early survival signals.
